3DR is a subscriber-driven research publication that issues comprehensive, very specific investment recommendations.
This Is What 3DR Offers:
- One Stock Recommendation a month, supported by a roughly 20 page research report.
- One Event-Driven Special Situations Recommendation, supported by a five- to 10-page report.
- An actively managed Model Covered Call Portfolio that provides additional ideas for generating recurring income.
The Thesis For Our Current Stock Recommendation Is:
Our focus in the early years after the 2008 financial crisis was on the deeply depressed dividend-paying multinational blue chips. Given the firmer financial underpinnings that now prevail, we've expanded our universe in search of compelling investments.
Tracking Rho's (year-old-plus) Recommendations:
|Stock||Buy Date||Sell Date||Current Price||Gain|
* - Gains based on price when sold
Since inception on August 13, 2009 through January 30, 2012, 3DR's Model Covered Call Portfolio gained 34.7%, versus 34.6% and 29.7% for the Dow and the S&P 500 Index, respectively. We stopped writing calls two years ago, however, in response to surging equity prices.
The overwhelming majority of our Event Driven Special Situation Recommendations have been profitable. Recent recommendations include Acadia Pharm., Arena Pharm., Halozyme, Keryx, MannKind, Prana Biotech., and Sarepta. Details are available upon request.
Benefits of Subscribing
- We cut through all the clutter and noise and highlight only the best investment opportunities.
- We keep abreast of all relevant developments affecting your investments and tell you when we think it's time to exit a position.
- Our recommendations are geared towards both building long-term wealth and generating current income.